ERBB2 and invasive ductal breast carcinoma: In the HR-positive population, the survival advantage of HER2-low tumors was more significant among women who were aged <50 y who had ductal adenocarcinoma and poorly differentiated tumors and those who received any chemotherapy (including AC and NAC) but not hormonal therapy (all p-interaction < 0.01) (Figure 6a).